search
Back to results

Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

Primary Purpose

Opioid Overdose

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
RELAY
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Opioid Overdose

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults (≥18 years)
  • English- or Spanish-speaking
  • Patient at a participating ED with nonfatal opioid OD.
  • Currently residing in NYC

Exclusion Criteria:

  • Unable to provide informed consent
  • Currently incarcerated, currently living in another controlled environment prohibiting research contacts, or currently in police custody
  • Known to be currently pregnant
  • Already participating in the study (patients will only be enrolled into the study once)
  • Already actively engaged in the Relay program (within the 90-day program window)
  • Speaks only Spanish, at a site and time period when no Spanish-speaking RA is available

Sites / Locations

  • NYU Langone Health

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Site-Directed Care (SDC)

Relay program (peer navigation)

Arm Description

Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.

Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.

Outcomes

Primary Outcome Measures

Number of opioid-related adverse events
The primary outcome is "opioid-related adverse events," which will include fatal and non-fatal opioid-involved overdose as well as substance use-related emergency department (ED) visits. ED visits and fatal overdoses in the 12-month period after baseline will be captured in administrative data sources. Other non-fatal opioid-involved overdose events will be captured by self-report in follow-up interviews through six months after baseline, and estimated for the second half of the 12-month follow-up period.

Secondary Outcome Measures

Initiation of medication for opioid use disorder (MOUD)
MOUD initiation will be measured at each study visit. MOUD is defined as use of methadone, buprenorphine, or naltrexone that is prescribed by an office-based provider or provided by a treatment program as treatment for OUD. Initiation is defined as receiving MOUD within the 90 days following the index visit, for individuals who received no MOUD for at least 2 weeks prior to the index visit.
Change in Overdose risk behaviors
Overdose risk behaviors will be measured using questions that measure the frequency in a period of 3 months at which participants engaged in a one or more of several different known risk behaviors for opioid overdose. The total risk score is an aggregation of responses to the individual questions.
Time to next opioid-involved overdose
Time to next opioid-involved overdose from the time of baseline, by self-report.
Percent of Emergency department visits for any cause
Frequency of ED visits for any cause (including visits that are not substance use-related) will be measured, using administrative data, to assess whether there are differences in overall acute care use representing potentially negative health events
Percent of Emergency department visits for opioid overdose
Frequency of ED visits for opioid overdose will be measured, using administrative data
Percent of Emergency Department visits for other (non-OD) substance use reasons.
Emergency department visits for other (non-OD) substance use reasons Frequency of ED visits for other (non-OD) substance use will be measured, using administrative data.
Percent of Self-reported opioid-involved overdose
Includes non-fatal overdose that did or did not result in an ED visit, by self report.

Full Information

First Posted
March 19, 2020
Last Updated
July 21, 2023
Sponsor
NYU Langone Health
Collaborators
Centers for Disease Control and Prevention
search

1. Study Identification

Unique Protocol Identification Number
NCT04317053
Brief Title
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
Official Title
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
October 8, 2020 (Actual)
Primary Completion Date
July 1, 2023 (Actual)
Study Completion Date
July 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health
Collaborators
Centers for Disease Control and Prevention

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The New York City (NYC) Department of Health and Mental Hygiene (DOHMH) has implemented Relay, a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. The proposed randomized controlled trial will evaluate the impact of Relay on preventing subsequent opioid-related adverse events. A total of 350 eligible individuals with nonfatal opioid OD presenting to one of four participating EDs will be enrolled and randomized to one of two arms: 1) site-directed care (SDC) or 2) Relay-peer-delivered OD education and treatment linkage, including 90 days of peer navigation. Outcomes will be measured for 12 months through interviews and administrative health data.
Detailed Description
Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Overdose

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
247 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Site-Directed Care (SDC)
Arm Type
No Intervention
Arm Description
Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.
Arm Title
Relay program (peer navigation)
Arm Type
Experimental
Arm Description
Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
Intervention Type
Behavioral
Intervention Name(s)
RELAY
Intervention Description
Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
Primary Outcome Measure Information:
Title
Number of opioid-related adverse events
Description
The primary outcome is "opioid-related adverse events," which will include fatal and non-fatal opioid-involved overdose as well as substance use-related emergency department (ED) visits. ED visits and fatal overdoses in the 12-month period after baseline will be captured in administrative data sources. Other non-fatal opioid-involved overdose events will be captured by self-report in follow-up interviews through six months after baseline, and estimated for the second half of the 12-month follow-up period.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Initiation of medication for opioid use disorder (MOUD)
Description
MOUD initiation will be measured at each study visit. MOUD is defined as use of methadone, buprenorphine, or naltrexone that is prescribed by an office-based provider or provided by a treatment program as treatment for OUD. Initiation is defined as receiving MOUD within the 90 days following the index visit, for individuals who received no MOUD for at least 2 weeks prior to the index visit.
Time Frame
1 month, 3 months
Title
Change in Overdose risk behaviors
Description
Overdose risk behaviors will be measured using questions that measure the frequency in a period of 3 months at which participants engaged in a one or more of several different known risk behaviors for opioid overdose. The total risk score is an aggregation of responses to the individual questions.
Time Frame
1 month, 3 months, 6 months
Title
Time to next opioid-involved overdose
Description
Time to next opioid-involved overdose from the time of baseline, by self-report.
Time Frame
1 month, 3 months, 6 months
Title
Percent of Emergency department visits for any cause
Description
Frequency of ED visits for any cause (including visits that are not substance use-related) will be measured, using administrative data, to assess whether there are differences in overall acute care use representing potentially negative health events
Time Frame
12 months
Title
Percent of Emergency department visits for opioid overdose
Description
Frequency of ED visits for opioid overdose will be measured, using administrative data
Time Frame
12 months
Title
Percent of Emergency Department visits for other (non-OD) substance use reasons.
Description
Emergency department visits for other (non-OD) substance use reasons Frequency of ED visits for other (non-OD) substance use will be measured, using administrative data.
Time Frame
12 months
Title
Percent of Self-reported opioid-involved overdose
Description
Includes non-fatal overdose that did or did not result in an ED visit, by self report.
Time Frame
1 month, 3 months, 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years) English- or Spanish-speaking Patient at a participating ED with nonfatal opioid OD. Currently residing in NYC Exclusion Criteria: Unable to provide informed consent Currently incarcerated, currently living in another controlled environment prohibiting research contacts, or currently in police custody Known to be currently pregnant Already participating in the study (patients will only be enrolled into the study once) Already actively engaged in the Relay program (within the 90-day program window) Speaks only Spanish, at a site and time period when no Spanish-speaking RA is available
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kelly Doran, MD
Organizational Affiliation
New York University
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD Sharing Time Frame
Beginning 9 months following article publication and ending 6 years after any reporting, publication, or presentation.
IPD Sharing Access Criteria
The investigator who proposed to use the data. Upon reasonable request. Upon request, study investigators will provide the research dataset to qualified investigators under a Data Use Agreement (DUA) that will require approval of the study Principal Investigators and each of the primary research team participating agencies (NYU and NYC Department of Health and Mental Hygiene).

Learn more about this trial

Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

We'll reach out to this number within 24 hrs